[go: up one dir, main page]

AR099837A1 - Terapia génica para la retinitis pigmentaria - Google Patents

Terapia génica para la retinitis pigmentaria

Info

Publication number
AR099837A1
AR099837A1 ARP150100879A ARP150100879A AR099837A1 AR 099837 A1 AR099837 A1 AR 099837A1 AR P150100879 A ARP150100879 A AR P150100879A AR P150100879 A ARP150100879 A AR P150100879A AR 099837 A1 AR099837 A1 AR 099837A1
Authority
AR
Argentina
Prior art keywords
gene therapy
pigmentary retinitis
viral particles
particles
retinitis
Prior art date
Application number
ARP150100879A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52829343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR099837(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR099837A1 publication Critical patent/AR099837A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan en la presente memoria métodos para tratar la retinitis pigmentaria usando partículas de AAV (virus adenoasociado) que codifican miR-708 (microARN-708). En un aspecto, las partículas víricas se administran en el ojo de un sujeto humano; por ejemplo, por inyección subretiniana. Están contempladas las partículas víricas que comprenden cápsides de AAV5 o mutantes de las mismas. Composición farmacéutica; kit; artículo manufacturado; ácido nucleico; construcción; vector; célula.
ARP150100879A 2014-03-21 2015-03-25 Terapia génica para la retinitis pigmentaria AR099837A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969027P 2014-03-21 2014-03-21

Publications (1)

Publication Number Publication Date
AR099837A1 true AR099837A1 (es) 2016-08-24

Family

ID=52829343

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100879A AR099837A1 (es) 2014-03-21 2015-03-25 Terapia génica para la retinitis pigmentaria

Country Status (36)

Country Link
US (3) US10383953B2 (es)
EP (3) EP3119437B1 (es)
JP (3) JP6669664B2 (es)
KR (3) KR20250172735A (es)
CN (2) CN106456660B (es)
AR (1) AR099837A1 (es)
AU (3) AU2015230942B2 (es)
CA (2) CA2943185C (es)
CL (1) CL2016002333A1 (es)
CR (1) CR20160480A (es)
DK (2) DK3119437T3 (es)
DO (1) DOP2016000237A (es)
EA (1) EA201691891A1 (es)
EC (1) ECSP16083000A (es)
ES (2) ES2760263T3 (es)
FI (1) FI3628334T3 (es)
HR (2) HRP20192141T1 (es)
HU (2) HUE063460T2 (es)
IL (3) IL247543B (es)
LT (2) LT3119437T (es)
MA (1) MA39390B2 (es)
MX (2) MX376190B (es)
MY (2) MY190726A (es)
NZ (1) NZ724622A (es)
PE (1) PE20161252A1 (es)
PH (1) PH12016501684B1 (es)
PL (2) PL3628334T3 (es)
PT (2) PT3628334T (es)
RS (2) RS64611B1 (es)
SG (3) SG11201607005UA (es)
SI (2) SI3628334T1 (es)
TW (2) TWI780401B (es)
UA (1) UA120050C2 (es)
UY (1) UY36044A (es)
WO (1) WO2015143418A2 (es)
ZA (1) ZA201605924B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201607005UA (en) 2014-03-21 2016-09-29 Genzyme Corp Gene therapy for retinitis pigmentosa
TN2017000354A1 (en) 2015-02-10 2019-01-16 Genzyme Corp VARIANT RNAi
WO2017093936A1 (en) * 2015-12-03 2017-06-08 Friedrich Miescher Institute For Biomedical Research Synp162, a promoter for the specific expression of genes in rod photoreceptors
WO2017093934A1 (en) * 2015-12-03 2017-06-08 Friedrich Miescher Institute For Biomedical Research Synp160, a promoter for the specific expression of genes in rod photoreceptors
JP6966442B2 (ja) * 2015-12-04 2021-11-17 ソルボンヌ・ユニヴェルシテSorbonne Universite プロモーター及びその使用
ES2923877T3 (es) * 2016-03-01 2022-10-03 Univ Florida Vectores VAA para el tratamiento de la retinitis pigmentosa dominante
AU2017293773A1 (en) * 2016-07-05 2019-02-21 The Johns Hopkins University CRISPR/Cas9-based compositions and methods for treating retinal degenerations
AR111188A1 (es) * 2017-03-21 2019-06-12 Univ Muenchen Ludwig Maximilians Terapia génica para el tratamiento de retinitis pigmentosa ligada al gen cngb1
IL273394B2 (en) * 2017-09-22 2025-04-01 Genzyme Corp RNAI variant
JP2020534837A (ja) * 2017-09-27 2020-12-03 シギロン セラピューティクス， インコーポレイテッドＳｉｇｉｌｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 活性細胞を含む方法、組成物、及び移植可能な要素
CN107961380B (zh) * 2017-11-23 2020-05-05 清华大学 试剂在制备药物中的用途、筛选药物的方法以及药物组合物
WO2019169245A1 (en) 2018-03-02 2019-09-06 Sigilon Therapeutics, Inc. Biocompatible hydrogel capsules and process for preparing same
US20210017509A1 (en) * 2018-03-23 2021-01-21 The Trustees Of Columbia University In The City Of New York Gene Editing for Autosomal Dominant Diseases
US12161760B2 (en) 2018-04-04 2024-12-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
CN112204145B (zh) * 2018-06-01 2024-03-26 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的组合物和方法
GB201817469D0 (en) * 2018-10-26 2018-12-12 Univ Oxford Innovation Ltd Gene therapy for retinal disease
CN111518813B (zh) * 2019-02-03 2023-04-28 武汉纽福斯生物科技有限公司 视紫红质的编码序列、其表达载体构建及其应用
SG11202109554XA (en) * 2019-03-04 2021-09-29 Univ Pennsylvania Neuroprotective gene therapy targeting the akt pathway
AU2020240136A1 (en) * 2019-03-21 2021-09-30 Ptc Therapeutics, Inc. Vector and method for treating angelman syndrome
MX2022001984A (es) * 2019-08-15 2022-05-19 Childrens Hospital Philadelphia Terapia combinada transgénica y de miarn derivado de intrones para el tratamiento de ataxia espinocerebelosa 1 (sca1).
JP2023510799A (ja) * 2020-01-10 2023-03-15 ソリッド・バイオサイエンシーズ・インコーポレーテッド 併用療法のためのウイルスベクター
TW202142552A (zh) * 2020-01-29 2021-11-16 美商健臻公司 用於眼部基因療法的經修飾的腺相關病毒衣殼蛋白及其使用方法
CN114521214A (zh) * 2020-07-24 2022-05-20 尔知渃米斯股份有限公司 视紫红质转录体特异性反式剪接核酶及其用途
AU2021319065A1 (en) * 2020-07-29 2023-02-16 University Of Florida Research Foundation, Incorporated Improved AAV-mediated X-linked retinoschisis therapies
US20220331241A1 (en) * 2021-04-16 2022-10-20 Regeneron Pharmaceuticals, Inc. Treatment of x-linked juvenile retinoschisis
TWI832531B (zh) * 2022-11-02 2024-02-11 慈濟學校財團法人慈濟大學 Rip1抑制劑或mlkl抑制劑用於治療或預防遺傳性視網膜失養症的用途
CN117625619B (zh) * 2023-12-05 2024-11-12 云舟生物科技(广州)股份有限公司 核酸分子及其作为特异启动子的应用
CN120230798A (zh) * 2023-12-29 2025-07-01 上海朗昇生物科技有限公司 用于视网膜基因递送的重组腺相关病毒载体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5985583A (en) * 1992-06-23 1999-11-16 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU781958C (en) 1999-08-09 2006-03-30 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
HU230406B1 (hu) 2001-11-13 2016-04-28 The Trustees Of The University Of Pennsylvania Eljárás adeno-asszociált vírus(AAV)szekvenciák detektálására és/vagy azonosítására és az azzal azonosított új szekvenciák izolálására
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
AU2005206410A1 (en) * 2004-01-22 2005-08-04 Dnavec Research Inc. Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
CA2683469C (en) * 2007-04-12 2019-11-26 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Genetic suppression and replacement
US20090214478A1 (en) 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
AU2010294197C9 (en) * 2009-09-10 2018-09-13 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application
ES2680915T3 (es) 2010-01-28 2018-09-11 The Children's Hospital Of Philadelphia Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP2634253B1 (en) 2010-10-27 2016-05-11 Jichi Medical University Adeno-associated virus virions for transferring genes into neural cells
EP2675902B1 (en) 2011-02-17 2019-03-27 The Trustees Of The University Of Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
JP5884152B2 (ja) 2011-07-29 2016-03-15 シャープ株式会社 基地局、端末、通信システムおよび通信方法
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
AU2013221212B2 (en) * 2012-02-17 2018-08-09 The Children's Hospital Of Philadelphia AAV vector compositions and methods for gene transfer to cells, organs and tissues
JP2015516143A (ja) * 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US20160046961A1 (en) 2012-05-25 2016-02-18 Emmanuelle Charpentier Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription
CN105120901A (zh) 2012-07-11 2015-12-02 宾夕法尼亚大学托管会 Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
CA2889020A1 (en) * 2012-10-23 2014-05-01 Cornell University Treatment of metastatic breast cancer
WO2015051052A2 (en) 2013-10-04 2015-04-09 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
SG11201607005UA (en) 2014-03-21 2016-09-29 Genzyme Corp Gene therapy for retinitis pigmentosa

Also Published As

Publication number Publication date
TW201622752A (zh) 2016-07-01
BR112016021017A2 (pt) 2017-10-03
EA201691891A1 (ru) 2017-01-30
DK3628334T3 (da) 2023-10-02
DK3628334T5 (da) 2024-09-02
MA39390A1 (fr) 2017-12-29
NZ762841A (en) 2023-11-24
HRP20231077T1 (hr) 2023-12-22
ES2760263T3 (es) 2020-05-13
SI3119437T1 (sl) 2020-01-31
PE20161252A1 (es) 2016-11-30
AU2015230942B2 (en) 2020-11-19
EP3628334B1 (en) 2023-06-28
IL247543B (en) 2020-07-30
CR20160480A (es) 2016-12-14
IL275918B (en) 2021-07-29
PT3119437T (pt) 2019-12-12
JP6669664B2 (ja) 2020-03-18
CN106456660B (zh) 2022-05-31
UA120050C2 (uk) 2019-09-25
HUE046454T2 (hu) 2020-03-30
US11103598B2 (en) 2021-08-31
EP3628334A1 (en) 2020-04-01
IL284741A (en) 2021-08-31
AU2024227776A1 (en) 2024-11-28
FI3628334T3 (fi) 2023-09-15
SG10201912968WA (en) 2020-02-27
AU2015230942A1 (en) 2016-10-13
KR20230006039A (ko) 2023-01-10
KR20250172735A (ko) 2025-12-09
RS59634B1 (sr) 2020-01-31
DOP2016000237A (es) 2016-10-16
CN106456660A (zh) 2017-02-22
EP4345165A3 (en) 2024-09-25
UY36044A (es) 2015-10-30
TW202021627A (zh) 2020-06-16
US12201698B2 (en) 2025-01-21
CA3254798A1 (en) 2025-12-01
JP7048563B2 (ja) 2022-04-05
US20170173183A1 (en) 2017-06-22
RS64611B1 (sr) 2023-10-31
WO2015143418A3 (en) 2015-11-19
CA2943185C (en) 2025-09-16
AU2021200988B2 (en) 2024-08-01
EP3119437A2 (en) 2017-01-25
DK3119437T3 (da) 2019-12-09
HRP20192141T1 (hr) 2020-02-21
EP4345165A2 (en) 2024-04-03
MY190726A (en) 2022-05-12
PL3119437T3 (pl) 2020-04-30
IL284741B (en) 2022-10-01
SI3628334T1 (sl) 2023-11-30
PH12016501684B1 (en) 2023-03-17
SG10201808218YA (en) 2018-10-30
AU2021200988A1 (en) 2021-03-11
LT3119437T (lt) 2019-12-27
CA2943185A1 (en) 2015-09-24
PT3628334T (pt) 2023-09-26
EP3119437B1 (en) 2019-09-04
CL2016002333A1 (es) 2017-05-26
US10383953B2 (en) 2019-08-20
US20200046851A1 (en) 2020-02-13
MA39390B2 (fr) 2022-04-29
MX2020010694A (es) 2020-11-06
JP2022084810A (ja) 2022-06-07
HUE063460T2 (hu) 2024-01-28
IL247543A0 (en) 2016-11-30
IL275918A (en) 2020-08-31
MX2016012201A (es) 2017-01-19
WO2015143418A2 (en) 2015-09-24
ECSP16083000A (es) 2017-02-24
MX376190B (es) 2025-03-07
PH12016501684A1 (en) 2016-10-03
LT3628334T (lt) 2023-09-25
MY203654A (en) 2024-07-11
NZ724622A (en) 2022-05-27
SG11201607005UA (en) 2016-09-29
PL3628334T3 (pl) 2023-12-18
JP2017509632A (ja) 2017-04-06
ZA201605924B (en) 2017-09-27
US20220054657A1 (en) 2022-02-24
CN115252823A (zh) 2022-11-01
IL284741B2 (en) 2023-02-01
JP2020059737A (ja) 2020-04-16
TWI706789B (zh) 2020-10-11
JP7534348B2 (ja) 2024-08-14
TWI780401B (zh) 2022-10-11
ES2957840T3 (es) 2024-01-26
KR20160127832A (ko) 2016-11-04

Similar Documents

Publication Publication Date Title
AR099837A1 (es) Terapia génica para la retinitis pigmentaria
MX2022004786A (es) Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular.
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
DOP2016000280A (es) Vectores de aav para la terapia génica de la retina y el snc
BR112019001887A2 (pt) composições e métodos para o tratamento de doença associada a cep290
MX2021004294A (es) Suministro mejorado de particulas virales al cuerpo estriado y al cortex.
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
EA201790534A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
WO2017044857A3 (en) Methods and compositions for the treatment of glaucoma
BR112017025045A2 (pt) plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
HUE055002T2 (hu) Nukleinsav-konstrukciók és génterápiás vektorok Wilson-kór kezelésében történõ alkalmazásra
CY1123793T1 (el) Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια
WO2016106458A8 (es) Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimización y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje
BR112018017077A2 (pt) terapias de combinação para tratamento de atrofia muscular espinhal
MX2019008105A (es) Virus.
EP3562937A4 (en) GENE THERAPY TO TREAT MUCOPOLYSACCHARIDOSIS TYPE II
BR112017017867A2 (pt) métodos e composições para tratamento de doenças oculares genéticas
HK1241924A1 (en) Adeno-associated viral vectors for treating myocilin (myoc) glaucoma

Legal Events

Date Code Title Description
FG Grant, registration